2min chapter

Biotech 2050 Podcast cover image

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Biotech 2050 Podcast

CHAPTER

Differentiation and Competition in Biopharmaceuticals

This chapter examines the rise of 'Me Too' drugs within the GLP-1 market, focusing on how a lucrative environment prompts pharmaceutical companies to favor established biological strategies. The discussion also underscores the implications of increased competition, including price reduction and market saturation in specific drug classes.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode